Wednesday, 28 Jun 2017

You are here

Rheumatic IRAEs Gaining Speed

Today I was fortunate to be a part of a From Bench to Bedside session on the topic of controlling the balance between cancer and autoimmunity, chaired by Drs. Leonard Calabrese and Xavier Mariette. Rheumatic IRAEs from checkpoint inhibitor therapy are growing rapidly in scope and rheumatologists must be aware of these complications, as they are certain to encounter this type of patient.

The first talk was by Dr. Antony Rosen (JHU) who discussed possible mechanisms underlying cancer in the setting of autoimmune disease, focusing on the strong associated between RNA pol III positive systemic sclerosis and the development of cancer. Next up was Dr. Aurélien Marabelle (France) who spoke from the oncology perspective on the paradigm shift in cancer therapy from drugs that target cancers to these checkpoint inhibitors that target the patient’s own immune system. He stressed the importance of interprofessional care of these patients by oncology and rheumatology.

I was thrilled to present the first abstract on our Cleveland Clinic experience with rheumatic IRAEs thus far. In our experience it seems that rheumatic IRAEs may not be self-limiting like some of the other system IRAEs (skin, gut), but rather here to stay, making the role of the rheumatologist all the more important. Dr. Rakiba Belkhir (Paris) presented the final abstract and shared a case series of 6 patients who developed ACPA-positive RA on checkpoint therapy.

Tak away points stressed that rheumatologists must become familiar with rheumatic IRAEs and engage with oncologists inter-professionally to optimize patient care, as their frequency will continue to increase.

Add new comment

More Like This

ACR Says Senate Healthcare Bill Falls Short of Protecting Americans with Rheumatic Disease

Dr. Sharad Lakhanpal, President of the American College of Rheumatology has responded to the Senate's proposed changes to healthcare coverage in the USA.

Highlights from EULAR 2017 - From RheumReports.com

Dr. Janet Pope reviews her favorite and least favorite presentations and abstracts from EULAR 2017. 

The RheumNow Week in Review – How to ACR/EULAR 23 June 2017

Dr. Jack Cush reviews his approach to attending and getting the most out of ACR or EULAR Congress meetings.

EULAR 2017 – Day 4 Highlights

Saturday was a day of big posters and special seminars at EULAR in Madrid.  In the morning, I passed on an interesting session on nailfold capillaroscopy led by Dr. M Cutolo and went to a JIA outcomes session. I reported on this in a video from day 4 (Saturday) called “Long-Term Comorbidities in JIA” – you can find it here.

Responder Criteria for Nonpharmalogical Treatment of Fibromyalgia.

Because of the subjective nature of fibromyalgia symptoms, tools for monitoring of disease activity and/or treatment assessment tools to evaluate effectiveness of nonpharmacological modalities are difficult to develop.